Department of Pharmaceutical Sciences, Division of Radiation Health, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Curr Drug Targets. 2010 Nov;11(11):1405-12. doi: 10.2174/1389450111009011405.
Radiotherapy of thoracic and chest wall tumors, if all or part of the heart was included in the radiation field, can lead to radiation-induced heart disease (RIHD), a late and potentially severe side effect. RIHD presents clinically several years after irradiation and manifestations include accelerated atherosclerosis, pericardial and myocardial fibrosis, conduction abnormalities, and injury to cardiac valves. The pathogenesis of RIHD is largely unknown, and a treatment is not available. Hence, ongoing pre-clinical studies aim to elucidate molecular and cellular mechanisms of RIHD. Here, an overview of recent pre-clinical studies is given, and based on the results of these studies, potential targets for intervention in RIHD are discussed.
胸部和胸壁肿瘤的放射治疗,如果心脏的全部或部分包含在放射野内,可能导致放射性心脏疾病(RIHD),这是一种迟发的、潜在严重的副作用。RIHD 在放射治疗后数年内出现临床症状,表现包括动脉粥样硬化加速、心包和心肌纤维化、传导异常以及心脏瓣膜损伤。RIHD 的发病机制在很大程度上尚不清楚,也没有有效的治疗方法。因此,目前正在进行临床前研究,旨在阐明 RIHD 的分子和细胞机制。本文概述了最近的临床前研究,并基于这些研究的结果,讨论了 RIHD 干预的潜在靶点。